09/08/2026
Protocol Activation NRG-GY038: A Randomized Phase II Trial of Sacituzumab Govitecan-Hziy (SG) and Bevacizumab versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer that has Progressed on Prior Maintenance PARP Inhibitor” Activation Date: September 4, 2026.